View Older Stories View More Recent Stories

Dec 4, 2018 08:30AM China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
Dec 4, 2018 08:30AM China’s National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6
Dec 3, 2018 08:00PM Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Dec 2, 2018 12:04PM Kite Announces Two-Year Data for Yescarta® (Axicabtagene Ciloleucel) in Patients With Refractory Large B-Cell Lymphoma
Nov 18, 2018 10:00PM China National Medical Products Administration (NMPA) Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for Chronic Hepatitis B Virus (HBV) Infection
Nov 12, 2018 05:01PM Gilead Sciences to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27
Nov 9, 2018 08:01AM Gilead Sciences (GILD) Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting
Nov 9, 2018 08:00AM Gilead Sciences (GILD) Announces Positive Phase 2 Results for GS-9674 in Primary PSC at The Liver Meeting
Nov 9, 2018 08:00AM Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting® 2018
Nov 9, 2018 08:00AM Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018
Nov 9, 2018 08:00AM Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018
Nov 1, 2018 09:00AM Gilead to Present Latest Scientific Research in Hematologic Malignancies and Solid Tumors at ASH 2018
Oct 30, 2018 07:17AM Gilead Sciences (GILD) Reports 96-Wk Data from Phase 3 Study of Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for HIV-1 Treatment in Adults New to HIV Therapy
Oct 30, 2018 06:36AM Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy
Oct 25, 2018 04:02PM Gilead Sciences Announces Fourth Quarter 2018 Dividend
Oct 11, 2018 04:05PM Gilead Sciences to Release Third Quarter 2018 Financial Results on Thursday, October 25, 2018
Oct 11, 2018 03:24PM Gilead Sciences (GILD) to Present New Data on Treatment and Diagnosis of Liver Diseases at Liver Meeting
Oct 11, 2018 03:23PM Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting® 2018
Oct 3, 2018 08:32AM Gilead Sciences (GILD) Reports 96-Week Results From Phase 3 Study of Biktarvy for Treatment of HIV-1 in Adults New to HIV Therapy
Oct 3, 2018 08:30AM Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy
Oct 3, 2018 06:10AM Gilead Sciences (GILD) Announces Hong Kong Department of Health Approval for Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide)
Oct 3, 2018 04:34AM Hong Kong Department of Health Approves Biktarvy(R) (bictegravir, emtricitabine, tenofovir alafenamide)
Sep 24, 2018 08:31AM Gilead Sciences (GILD) Subsidiary to Launch Authorized Generics of Epclusa and Harvoni
Sep 24, 2018 08:30AM Gilead Subsidiary to Launch Authorized Generics of Epclusa® (Sofosbuvir/Velpatasvir) and Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C
Sep 12, 2018 08:33AM Gilead Sciences (GILD) Reports Collaboration with Precision BioSciences to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing
Sep 12, 2018 08:31AM Gilead Sciences and Precision BioSciences Announce Collaboration to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing
Aug 30, 2018 04:01PM Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 12
Aug 28, 2018 05:00PM Gilead Sciences Appoints Laura Hamill as Executive Vice President, Worldwide Commercial Operations
Aug 27, 2018 06:36AM Gilead (GILD) Announces Yescarta Receives European Marketing Authorization for Treatment of R/R DLBCL and PMBCL
Aug 27, 2018 06:34AM Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy
Aug 14, 2018 05:01PM Gilead Sciences (GILD) Chief Medical Officer Andrew Cheng to Leave
Aug 14, 2018 05:00PM Gilead Sciences Announces Executive Promotions
Aug 7, 2018 08:16AM Express Scripts (ESRX) Announces 2019 National Preferred Formulary Exclusion List Changes
Aug 6, 2018 06:11AM Gilead Sciences (GILD) Reports Chinese (CNDA) Approval of Genvoya (Elvitegravir, Cobicistat, Emtricitabine & Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Aug 6, 2018 06:09AM China National Drug Administration Approves Gilead’s Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), a Single Tablet Regimen for the Treatment of HIV-1 Infection
Jul 25, 2018 04:02PM Gilead Sciences Announces Third Quarter 2018 Dividend
Jul 25, 2018 04:01PM Gilead Sciences (GILD) CEO John F. Milligan to Step Down
Jul 25, 2018 04:00PM Gilead Sciences Announces CEO John F. Milligan to Step Down
Jul 24, 2018 08:05AM Gilead Sciences (GILD) Reports New Data on the Impact of Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate)
Jul 24, 2018 08:00AM Gilead Announces New Data on the Impact of Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Pre-Exposure Prophylaxis (PrEP) on the Number of HIV Diagnoses in the United States
Jul 13, 2018 04:01PM Gilead Sciences to Release Second Quarter 2018 Financial Results on Wednesday, July 25, 2018
Jul 9, 2018 04:30PM Michael Amoroso to Join Kite as Senior Vice President and Head of Worldwide Commercial, Cell Therapy
Jun 29, 2018 07:56AM Gilead Sciences (GILD) Reports Positive Opinion from European CHMP for Yescarta (axicabtagene ciloleucel)
Jun 29, 2018 07:54AM European CHMP Adopts Positive Opinion for Yescarta® (axicabtagene ciloleucel) for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy
Jun 25, 2018 08:04AM Gilead Sciences (GILD) Announces EC Granted Marketing Authorization for its Biktarvy for Treatment of HIV-1 Infection
Jun 25, 2018 08:03AM European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
Jun 11, 2018 08:30AM Gilead Sciences’ Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia
Jun 4, 2018 05:01PM Gilead Sciences (GILD) Names Andrew Dickinson Promoted to EVP, Corporate Development and Strategy; Martin Silverstein to Leave
Jun 4, 2018 05:00PM Gilead Sciences Announces Leadership Changes in Corporate Development and Strategy
Jun 4, 2018 09:01AM Kite (GILD) Announces Initial Results From a Phase 1 Study of TCR Cell Therapy in HPV-16-Positive Solid Tumors
View More Recent Stories View Older Stories